Welcome to our dedicated page for ORGANON & news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & stock.
Organon & Co. reports developments as a global healthcare company with portfolios in Women's Health and General Medicines, including biosimilars. Company news commonly covers operating results, product and regulatory updates, and clinical data for medicines such as VTAMA cream for atopic dermatitis and plaque psoriasis, biosimilar approvals including POHERDY, and established women's health brands and devices such as Nexplanon, Follistim, and Jada.
Updates also address capital-structure disclosures, governance matters, shareholder voting topics, and material agreements, alongside the company's commercial activity across more than 140 markets.
Organon (NYSE: OGN) celebrates its launch as a global women's health company with an opening bell ceremony at the NYSE. The company focuses on addressing women's health needs, emphasizing reproductive health and unique health issues. Organon's portfolio includes over 60 products across 140 markets, generating approximately $6.5 billion annually, with 80% from outside the U.S. Key growth areas include Women’s Health, Biosimilars, and Established Brands. The firm aims to enhance women's health through innovation and has a majority female board to guide its mission.